Collaborative Centre for Genomic Cancer Medicine
Pioneering breakthroughs for people with cancer
Australia’s first academic genomics centre inside a cancer hospital
The Collaborative Centre for Genomic Cancer Medicine is a joint venture between the University of Melbourne and Peter MacCallum Cancer Centre.
More than 200 researchers and clinicians work across the two organisations to bring genomics into everyday cancer care: better prevention and earlier diagnosis, treatment matched to each person’s cancer, and fair access to all of it, wherever someone lives.
Our work runs from the lab to the clinic to the health system: understanding what drives cancers, building the tests and platforms that make genomics part of routine care, and making the case for everyone to have access.
Our research groups
The Collaborative Centre is home to more than 200 researchers working in groups and labs that cover the whole path from discovery to care: cancer biology, pathology and genomic platforms, clinical trials, primary and palliative care, and the health economics of making precision medicine available to everyone. Across blood, bowel, prostate and rare cancers, and more.
What we do
Transforming cancer pathology
We’re driving innovation in technology and developing new ways to improve cancer diagnosis and screening – including tests that can detect tumours with a single drop of blood. Our goal is to ensure every Australian with cancer gets the right genomic tests and treatments tailored to fit their unique genetic blueprint.
Making genomics the standard of care
Genomics is a powerful tool. When it comes to cancer care, it should be used routinely. We’re supporting clinical trials and developing new protocols so people with cancer have equitable access to genomics, making its insights more affordable and effective.
Addressing precision medicine’s data dilemma
We’re building better data solutions, that will pave the way for future research translation and discovery. This includes ensuring the datasets we use to assess new treatments include people from all backgrounds, to truly personalise cancer medicine.
Improving access to precision cancer care
Our researchers are striving to understand the health economic forces that will facilitate access to precision medicine, so each individual has equal access no matter where they live, their financial situation or the type of cancer they have. We’re working alongside industry to make the case for publicly funded genomic tests and cancer-fighting drugs.